Related references
Note: Only part of the references are listed.Interstitial Lung Disease in Undifferentiated Forms of Connective Tissue Disease
Aryeh Fischer et al.
ARTHRITIS CARE & RESEARCH (2015)
Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review
Michael Mahler et al.
AUTOIMMUNITY REVIEWS (2014)
High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis
Keishi Oda et al.
RESPIRATORY RESEARCH (2014)
Rituximab in severe, treatment-refractory interstitial lung disease
Gregory J. Keir et al.
RESPIROLOGY (2014)
Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis
Rohit Aggarwal et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis A Randomized, Placebo-Phase Trial
Chester V. Oddis et al.
ARTHRITIS AND RHEUMATISM (2013)
Interstitial lung disease in connective tissue disorders
Aryeh Fischer et al.
LANCET (2012)
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A. Fernandez-Nebro et al.
LUPUS (2012)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Dimitrios Daoussis et al.
RHEUMATOLOGY (2010)
Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease
Shikha Mittoo et al.
RESPIRATORY MEDICINE (2009)
Rituximab treatment of the anti-synthetase syndrome-a retrospective case series
Marthe Sem et al.
RHEUMATOLOGY (2009)
Progressive preclinical interstitial lung disease in rheumatoid arthritis
Bernadette R. Gochuico et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab
D. McGonagle et al.
RHEUMATOLOGY (2008)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Interstitial lung disease in scleroderma
B White
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2003)
Share Paper
